BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that it has completed its first royalty payment to NanoLogix, Inc (Other OTC: NNLX) for the licensing rights to the technology used in the Designer Diagnostics test kits.
